Would be interesting if that is why Elite held onto its 10%l Novel stake......I think this is interesting that an integral board member used to work at Actavis.....

Kevin Anderson – Vice President, Business Development

Kevin Anderson joined Novel Laboratories, Inc. in July 2008 as Vice President of Business Development. With over to 20 years of experience in Sales & Marketing in the pharmaceutical industry, Kevin seeks and evaluates new business relationships and opportunities for Novel and manages existing relationships. He engages in concept and brand development, assessment of marketing opportunities and target markets, intelligence gathering on customers and competitors, generating leads for possible sales, follow-up sales activity and formal proposal writing and business model design.

Prior to joining Novel, Kevin held senior management positions with Actavis, a dynamic worldwide generic company, and with Amide Pharmaceutical a US generic pharmaceutical manufacturer. At Actavis he led the commercial integration of the US acquired companies Amide Pharmaceutical, Alpharma/Purepac, and Abrika. Prior to the Actavis acquisition, his role at Amide was Vice President of Sales & Marketing where he grew profitable sales in excess of $125 million. Kevin has developed strategic and lasting relationships with key customer executives in the following trade organizations: Chain Drug (NACDS), Mail Order Pharmacy (PCMA) and Wholesaler/Distributor (HDMA).